← Back to all trials
Enrolling By Invitation
NCT06925685
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product
Conditions: Hematologic Malignancies, Solid Tumors
Sex: All
Healthy volunteers: No
Enrollment: 50
Sponsor: Allogene Therapeutics
Location: Circuit Clinical Buffalo New York
Summary
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.
Eligibility Criteria
Inclusion Criteria:
* Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study
Exclusion Criteria:
* Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor
Source: ClinicalTrials.gov (NCT06925685). StuddyBuddy aggregates publicly available trial information.
